Inhibrx Biosciences, Inc. (INBX)
123.41
-0.52
(-0.42%)
USD |
NASDAQ |
Aug 28, 16:00
123.34
-0.07
(-0.06%)
After-Hours: 20:00
Inhibrx Biosciences 1 Year Total Returns (Daily) : 342.6% for Aug. 28, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| August 28, 2026 | 342.6% |
| August 27, 2026 | 352.3% |
| August 26, 2026 | 383.7% |
| August 25, 2026 | 390.1% |
| August 24, 2026 | 319.8% |
| August 21, 2026 | 328.9% |
| August 20, 2026 | 306.2% |
| August 19, 2026 | 341.2% |
| August 18, 2026 | 296.4% |
| August 17, 2026 | 294.4% |
| August 14, 2026 | 269.1% |
| August 13, 2026 | 311.6% |
| August 12, 2026 | 348.7% |
| August 11, 2026 | 331.7% |
| August 10, 2026 | 342.1% |
| August 07, 2026 | 315.5% |
| August 06, 2026 | 308.9% |
| August 05, 2026 | 300.7% |
| August 04, 2026 | 283.2% |
| August 03, 2026 | 283.0% |
| July 31, 2026 | 274.3% |
| July 30, 2026 | 268.6% |
| July 29, 2026 | 226.7% |
| July 28, 2026 | 224.3% |
| July 27, 2026 | 257.2% |
| Date | Value |
|---|---|
| July 24, 2026 | 253.5% |
| July 23, 2026 | 266.4% |
| July 22, 2026 | 275.9% |
| July 21, 2026 | 296.1% |
| July 20, 2026 | 243.9% |
| July 17, 2026 | 270.0% |
| July 16, 2026 | 276.6% |
| July 15, 2026 | 297.3% |
| July 14, 2026 | 306.0% |
| July 13, 2026 | 323.4% |
| July 10, 2026 | 343.3% |
| July 09, 2026 | 396.4% |
| July 08, 2026 | 387.0% |
| July 07, 2026 | 449.0% |
| July 06, 2026 | 494.9% |
| July 02, 2026 | 519.9% |
| July 01, 2026 | 547.2% |
| June 30, 2026 | 564.0% |
| June 29, 2026 | 561.8% |
| June 26, 2026 | 541.0% |
| June 25, 2026 | 539.2% |
| June 24, 2026 | 544.6% |
| June 23, 2026 | 538.1% |
| June 22, 2026 | 524.9% |
| June 18, 2026 | 511.8% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| AnaptysBio, Inc. | 319.4% |
| 4D Molecular Therapeutics, Inc. | 137.4% |
| Design Therapeutics, Inc. | 167.9% |
| Agenus, Inc. | 80.24% |
| Amgen, Inc. | 55.58% |